Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis
详细信息 查看全文
- 作者：Naglaa M El-Lakkany (1)
Olfat A Hammam (2)
Walaa H El-Maadawy (1)
Afkar A Badawy (2)
Afaf A Ain-Shoka (3)
Fatma A Ebeid (1) - 关键词：Schistosoma mansoni ; silymarin ; praziquantel ; liver fibrosis ; hydroxyproline ; transforming growth factor ; β1 ; matrix metalloproteinase ; 2 ; mast cells
- 刊名：Parasites & Vectors
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：5
- 期：1
- 全文大小：1204KB
- 参考文献：1. Burke ML, McManus DP, Ramm GA, Duke M, Li Y, Jones MK, Gobert GN: Temporal expression of chemokines dictates the hepatic inflammatory infiltrate in a murine model of schistosomiasis. / PLOS Negl Trop Dis 2010, 4:e598. CrossRef
2. Cheever AW, Jankovic D, Yap GS, Kullberg MC, Sher A, Wynn TA: Role of cytokines in the formation and downregulation of hepatic circumoval granulomas and hepatic fibrosis in Schistosoma mansoni infected mice. / Mem Inst Oswaldo Cruz 1998, 93:25-2. CrossRef
3. Kresina TF, He Q, Degli Esposti S, Zern MA: Gene expression of transforming growth factor 1 and extracellular matrix proteins in murine Schistosoma mansoni infection. / Gastroenterology 1994, 107:773-80. CrossRef
4. Du WD, Zhang YE, Zhai WR, Zhou XM: Dynamic changes of type I, II and IV collagen synthesis and distribution of collagen-producing cells in carbon tetrachloride induced rat liver fibrosis. / World J Gastroenterol 1999, 5:397-03.
5. Wang YF, Li QF, Wang H, Mao Q, Wu CQ: Effects of vitamin E on experimental hepatic fibrosis in rats. / World J Gastroenterol 1998, 4:157.
6. Sugihara A, Tsujimura T, Fujita Y, Nakata Y, Terada N: Evaluation of role of mast cells in the development of liver fibrosis using mast cell-deficient rats and mice. / J Hepatol 1999, 30:859-67. CrossRef
7. Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE: Mast cell infiltration and chemokine expression in progressive renal disease. / Kidney Int 2003, 64:906-13. CrossRef
8. Jeong D, Lee G, Jeong W, Do S, Yang H, Yuan D, Park H, Kim K, Jeong K: Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl 4 induced hepatic fibrosis. / World J Gastroenterol 2005, 11:1141-148.
9. Takahara T, Furui K, Yata Y, Jin B, Zhang LP, Nambu S, Sato H, Seiki M, Watanabe A: Dual expression of matrix metalloproteinase-2 and membrane-type-1-matrix metalloproteinase in fibrotic human livers. / Hepatology 1997, 26:1521-529. CrossRef
10. Albanis E, Safadi R, Friedman S: Treatment of hepatic fibrosis: almost there. / Curr Gastroenterol Rep 2003, 5:48-6. CrossRef
11. Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH: Drugs for the control of parasitic diseases: current status and development in schistosomiasis. / Trends Parasitol 2003, 19:509-15. CrossRef
12. Homeida MA, el Tom I, Nash T, Bennett JL: Association of the therapeutic activity of praziquantel with the reversal of Symmers' fibrosis induced by Schistosoma mansoni . / Am J Trop Med Hyg 1991, 45:360-65.
13. Valenzuela A, Garrido A: Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. / Biol Res 1994, 27:105-12.
14. Down WH, Chasseaud LF, Grundy RK: Effect of silybin on the hepatic microsomal drug metabolizing enzyme system in the rat. / Arzneim Forsch/Drug Res 1974, 24:1986-988.
15. Fuchs EC, Weyhenmeyer R, Weiner OH: Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts. / Arzneim Forsch/Drug Res 1997, 47:1383-387.
16. Mata-Santos HA, Lino FG, Rocha CC, Paiva CN, Castelo Branco MT, Pyrrho Ados S: Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis. / Parasitol Res 2010, 107:1429-434. CrossRef
17. He Q, Kim J, Sharma RP: Silymarin protects against liver damage in BALB/c mice exposed to Fumonisin B1 despite increasing accumulation of free sphingoid bases. / Toxicol Sci 2004, 80:335-42. CrossRef
18. Gonnert R, Andrews P: Praziquantel, a new broad-spectrum antischistosomal agent. / Z Parasitenkd 1977, 52:129-50. CrossRef
19. Liang YS, John BI, Boyd DA: Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles. / Proceeding of the 1st Sino-American Symposium 1987, 1:34-8.
20. Duvall RH, De Witt WB: An improved perfusion technique for recovering adult schistosomes from laboratory animals. / Am J Trop Med Hyg 1967, 16:483-86.
21. Cheever AW: Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. / Bull World Health Organ 1968, 39:328-31.
22. Pellegrino J, Oliveira CA, Faria J, Cunha AS: New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. / Am J Trop Med Hyg 1962, 11:201-15.
23. Von Lichtenberg FC: Host response to eggs of Schistosoma mansoni . I. Granuloma formation in the sensitized laboratory mouse. / Am J Pathol 1962, 41:711-31.
24. Ellman G: Tissue sulfhydryl groups. / Arch Biochem Biophys 1959, 88:70-7. CrossRef
25. Woessner JF: The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. / Arch Biochem Biophys 1961, 93:440-47. CrossRef
26. Hsu SM, Raine L: Protein A, avidin and biotin in immunohistochemistry. / J Histochem Cytochem 1981, 29:1349-353. CrossRef
27. Kim CK, Lim JH, Lee WJ: Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. / J Ultrasound Med 2001, 20:99-04.
28. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S: Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. / Cancer 1998, 82:1359-366. CrossRef
29. Churukian CJ, Schenk EA: A toluidine blue method for demonstrating mast cells. / J Histopathol 1981, 4:85-6.
30. Kamel R, Dahiya P, Palaskar S, Shetty VP: Comparative analysis of mast cell count in normal oral mouse and oral pyogenic granuloma. / J Clin Exp Dent 2011, 3:e1-. CrossRef
31. Andrade ZA: Schistosomiasis and hepatic fibrosis regression. / Acta Tropica 2008, 108:79-2. CrossRef
32. Abdul-Ghani RA, Hassan AA: Murine schistosomiasis as a model for human schistosomiasis mansoni : similarities and discrepancies. / Parasitol Res 2010, 107:1-. CrossRef
33. Naik SR, Panda VS: Antioxidant and hepatoprotective effects of Ginkgo biloba phytosomes in carbon tetrachloride-induced liver injury in rodents. / Liver Int 2007, 27:393-99. CrossRef
34. Oliveira SA, Souza BS, Guimaraes-Ferreira CA, Barreto ES, Souza SC, Freitas LA, Ribeiro-Dos-Santos R, Soares MB: Therapy with bone marrow cells reduces liver alterations in mice chronically infected by Schistosoma mansoni . / Braz J Med Biol Res 2009, 42:812-15. CrossRef
35. Ala-kokko L, Stenback F, Ryhanen L: Preventive effect of malotilate on carbon tetrachloride-induced liver damage and collagen accumulation in the rat. / Biochem J 1987, 246:503-09.
36. El-Meneza S, Olds GR, Kresina TF, Mahmoud AAF: Dynamics of hepatic connective tissue matrix constituents during murine Schistosoma mansoni infection. / Hepatology 1989, 9:50-6. CrossRef
37. Singh KP, Gerard HC, Hudson AP, Boros DL: Dynamics of collagen, MMP and TIMP gene expression during the granulomatous, fibrotic process induced by Schistosoma mansoni eggs. / Ann Trop Med Parasitol 2004, 98:581-93. CrossRef
38. Loebermann M, Sombetzki M, Langner C, Fuchsbichler A, Gumhold J, Silbert D, Riebold D, Holtfreter M, Fickert P, Nizze H, Trauner M, Reisinger EC: Imbalance of pro- and antifibrogenic genes and bile duct injury in murine Schistosoma mansoni infection-induced liver fibrosis. / Trop Med Int Health 2009, 14:1418-425. CrossRef
39. Gazák R, Walterová D, Kren V: Silybin and silymarin-new and emerging applications in medicine. / Curr Med Chem 2007, 14:315-38. CrossRef
40. Zhao XY, Wang BE, Wang TL, Li XM: Inhibitory effects of silymarin on hepatic fibrosis induced by dimethylnitrosamine: experiment with rats. / Zhonghua Yi Xue Za Zhi 2006, 86:2563-566.
41. Zhao XY, Zeng X, Li XM, Wang TL, Wang BE: Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate Cells. / Clin Exp Pharmacol Physiol 2009, 36:963-68. CrossRef
42. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, Pinzani M: Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. / J Hepatol 2009, 50:1102-111. CrossRef
43. Weber S, Kruger-Krasagakes S, Grabbe J, Zuberbier T, Czarnetzki BM: Mast cells. / Int J Dermatol 1995, 34:1-0. CrossRef
44. Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Jin W, Kwon YH, Shin MK, Yoo TM, Kang JH, Park CS: Deleterious effects of silymarin on the expression of genes controlling endothelial nitric oxide synthase activity in carbon tetrachloride-treated rat livers. / Life Sci 2009, 85:281-90. CrossRef
45. Pradeep K, Mohan CV, Gobianand K, Karthikeyan S: Silymarin modulates the oxidant-antioxidant imbalance during diethylnitrosamine induced oxidative stress in rats. / Eur J Pharmacol 2007, 560:110-16. CrossRef
46. Kiruthiga PV, Shafreen RB, Pandian SK, Devi KP: Silymarin protection against major reactive oxygen species released by environmental toxins: exogenous H2O2 exposure in erythrocytes. / Basic Clin Pharmacol Toxicol 2007, 100:414-19. CrossRef
47. Chen MG: Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. / Acta Tropica 2005, 96:168-76. CrossRef
48. Berhe N, Myrvang B, Gundersen SG: Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia. / Am J Trop Med Hyg 2008, 78:228-34.
49. Frenzel K, Grigull L, Odongo-Aginya E, Ndugwa CM, Loroni-Lakwo T, Schweigmann U, Vester U, Spannbrucker N, Doehring E: Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni -induced hepatosplenic lesions in northern Uganda. / Am J Trop Med Hyg 1999, 60:927-31.
50. Singh KP, Gerard HC, Hudson AP, Boros DL: Expression of matrix metalloproteinases and their inhibitors during the resorption of schistosome egg-induced fibrosis in praziquantel-treated mice. / Immunology 2004, 111:343-52. CrossRef
51. Liang Y, Luo J, Yuan Q, Zheng D, Liu Y, Shi L, Chen A, Ren Y, Sun K, Sun Y, Wang Y, Zhang Z: New insight into the antifibrotic effects of praziquantel on mice in infection with Schistosoma japonicum . / PLOS One 2011, 6:e20247. CrossRef
52. Song Z, Deaciuc I, Song M, Lee DY, Liu Y, Ji X, Mc Clain C: Silymarin protects against acute ethanol-induced hepatotoxicity in mice. / Alcohol Clin Exp Res 2006, 30:407-13. CrossRef
53. Velebny S, Hrckova G, Kogan G: Impact of treatment with praziquantel, silymarin and/or beta-glucan on pathophysiological markers of liver damage and fibrosis in mice infected with Mesocestoides vogae (Cestoda) tetrathyridia. / J Helminthol 2008, 82:211-19. CrossRef
54. Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS: Immunostimulatory effect of Silybum marianum (milk thistle) extract. / Med Sci Monit 2002, 8:BR439-43.
55. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA: Milk thistle for the treatment of liver disease: A systematic review and meta-analysis. / Am J Med 2002, 113:506-15. CrossRef - 作者单位：Naglaa M El-Lakkany (1)
Olfat A Hammam (2)
Walaa H El-Maadawy (1)
Afkar A Badawy (2)
Afaf A Ain-Shoka (3)
Fatma A Ebeid (1)
1. Department of Pharmacology, Theodor Bilharz Research Institute, Warrak El-Hadar, P.O Box 30, Imbaba, Giza, 12411, Egypt
2. Department of Pathology, Theodor Bilharz Research Institute, Warrak El-Hadar, P.O Box 30, Imbaba, Giza, 12411, Egypt
3. Department of Pharmacology, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo, 11562, Egypt
文摘
Background Praziquantel (PZQ) is an isoquinoline derivative (2-cyclohexylcarbonyl-1, 2, 3, 6, 7, 11b-hexahydro-4H-pyrazino{2,1-a}-isoquinoline-4-one), and is currently the drug of choice for all forms of schistosomiasis. Silymarin, a standardized milk thistle extract, of which silibinin is the main component, is known for its hepatoprotective, anti-inflammatory, antioxidant activities, and hepatocyte regeneration. This study investigates the anti-inflammatory/anti-fibrotic effects of silymarin and/or PZQ on schistosomal hepatic fibrosis. Methods Schistosoma mansoni-infected mice were divided into two large groups (I & II), each with four subgroups and were run in parallel. (i) Infected untreated; (ii) treated with silymarin, starting from the 4th (3 weeks before PZQ therapy) or 12th (5 weeks after PZQ therapy) weeks post infection (PI); (iii) treated with PZQ in the 7th week PI; and (iv) treated with silymarin, as group (ii) plus PZQ as group (iii). Comparable groups of uninfected mice run in parallel with the infected groups. Mice of groups I and II were killed 10 and 18 weeks PI, respectively. Hepatic content of hydroxyproline (HYP), serum levels and tissue expression of matrix metalloproteinase-2 (MMP-2), transforming growth factor-β1 (TGF-β1) and number of mast cells were determined. In addition, parasitological, biochemical and histological parameters that reflect disease severity and morbidity were examined. Results Silymarin caused a partial decrease in worm burden; hepatic tissue egg load, with an increase in percentage of dead eggs; modulation of granuloma size, with significant reduction of hepatic HYP content; tissue expression of MMP-2, TGF-β1; number of mast cells, with conservation of hepatic reduced glutathione (GSH). PZQ produced complete eradication of worms, eggs and alleviated liver inflammation and fibrosis. The best results were obtained, in most parameters studied, in groups of mice treated with silymarin in addition to PZQ. Conclusions Our results point to silymarin as a promising anti-inflammatory and anti-fibrotic agent; it could be introduced as a therapeutic tool with PZQ in the treatment of schistosomal liver fibrosis, but further studies on mechanisms of silymarin and PZQ in chronic liver diseases may shed light on developing therapeutic methods in clinical practice.